HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiarrhythmic effect of Mercurascan in patients after surgical treatment of ischaemic heart disease.

Abstract
Premature ventricular contractions are relatively often encountered in patients after surgical treatment of ischaemic heart disease. Mercurascan (MSC), given at 0.05 mg/kg of body weight, favourably affected both the incidence and duration of arrhythmia. Unlike other antiarrhythmics, MSC did not affect the heart rate nor blood pressure. Postoperative treatment of ventricular arrhythmia with MSC is a promising procedure and merits further clinical and experimental investigation.
AuthorsZ Vránová, M Janota, P Málek, M Vrána
JournalCor et vasa (Cor Vasa) Vol. 18 Issue 1 Pg. 77-9 ( 1976) ISSN: 0010-8650 [Print] Czech Republic
PMID57025 (Publication Type: Journal Article)
Chemical References
  • Anti-Arrhythmia Agents
  • Fluoresceins
  • Merbromin
Topics
  • Anti-Arrhythmia Agents (therapeutic use)
  • Arrhythmias, Cardiac (drug therapy, etiology)
  • Coronary Artery Bypass (adverse effects)
  • Coronary Disease (surgery)
  • Drug Evaluation
  • Fluoresceins (therapeutic use)
  • Humans
  • Merbromin (therapeutic use)
  • Monitoring, Physiologic
  • Postoperative Complications (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: